These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 27997533)

  • 1. Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.
    Parkinson CA; Gale D; Piskorz AM; Biggs H; Hodgkin C; Addley H; Freeman S; Moyle P; Sala E; Sayal K; Hosking K; Gounaris I; Jimenez-Linan M; Earl HM; Qian W; Rosenfeld N; Brenton JD
    PLoS Med; 2016 Dec; 13(12):e1002198. PubMed ID: 27997533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.
    Kim YM; Lee SW; Lee YJ; Lee HY; Lee JE; Choi EK
    J Gynecol Oncol; 2019 May; 30(3):e32. PubMed ID: 30887755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
    Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
    PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of TP53 mutations in circulating tumour DNA in high grade serous ovarian carcinoma using next generation sequencing technologies.
    Calapre L; Giardina T; Beasley AB; Reid AL; Stewart C; Amanuel B; Meniawy TM; Gray ES
    Sci Rep; 2023 Jan; 13(1):278. PubMed ID: 36609632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
    Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
    PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients.
    Madic J; Kiialainen A; Bidard FC; Birzele F; Ramey G; Leroy Q; Rio Frio T; Vaucher I; Raynal V; Bernard V; Lermine A; Clausen I; Giroud N; Schmucki R; Milder M; Horn C; Spleiss O; Lantz O; Stern MH; Pierga JY; Weisser M; Lebofsky R
    Int J Cancer; 2015 May; 136(9):2158-65. PubMed ID: 25307450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in circulating tumor DNA detected in the postoperative period predict poor survival in patients with ovarian cancer.
    Chao A; Chen SJ; Chen HC; Tan KT; Hsiao W; Jung SM; Yang LY; Huang KG; Chou HH; Huang HJ; Chang TC; Chao AS; Lee YH; Wu RC; Lai CH
    Biomed J; 2023 Oct; 46(5):100563. PubMed ID: 36208860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras/Raf pathway with TP53.
    Zhong F; Zhu T; Pan X; Zhang Y; Yang H; Wang X; Hu J; Han H; Mei L; Chen D; Wang K; Zhou X; Li X; Dong X
    Cancer Med; 2019 Jul; 8(8):3928-3935. PubMed ID: 31124283
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Vitale SR; Groenendijk FH; van Marion R; Beaufort CM; Helmijr JC; Dubbink HJ; Dinjens WNM; Ewing-Graham PC; Smolders R; van Doorn HC; Boere IA; Berns EMJJ; Helleman J; Jansen MPHM
    Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32156073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis.
    Schwarz RF; Ng CK; Cooke SL; Newman S; Temple J; Piskorz AM; Gale D; Sayal K; Murtaza M; Baldwin PJ; Rosenfeld N; Earl HM; Sala E; Jimenez-Linan M; Parkinson CA; Markowetz F; Brenton JD
    PLoS Med; 2015 Feb; 12(2):e1001789. PubMed ID: 25710373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clonal Evolution of
    Garziera M; Cecchin E; Giorda G; Sorio R; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Ecca F; Canzonieri V; Toffoli G
    Cells; 2019 Oct; 8(10):. PubMed ID: 31581548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients.
    van Ginkel JH; Huibers MMH; van Es RJJ; de Bree R; Willems SM
    BMC Cancer; 2017 Jun; 17(1):428. PubMed ID: 28629339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.
    Tie J; Kinde I; Wang Y; Wong HL; Roebert J; Christie M; Tacey M; Wong R; Singh M; Karapetis CS; Desai J; Tran B; Strausberg RL; Diaz LA; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Ann Oncol; 2015 Aug; 26(8):1715-22. PubMed ID: 25851626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
    Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.
    Campani C; Imbeaud S; Couchy G; Ziol M; Hirsch TZ; Rebouissou S; Noblet B; Nahon P; Hormigos K; Sidali S; Seror O; Taly V; Ganne Carrie N; Laurent-Puig P; Zucman-Rossi J; Nault JC
    Gut; 2024 Oct; 73(11):1870-1882. PubMed ID: 39054058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer.
    Qu H; Xia Y; Li X
    Curr Gene Ther; 2020; 20(4):313-320. PubMed ID: 32851960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues.
    Krimmel JD; Schmitt MW; Harrell MI; Agnew KJ; Kennedy SR; Emond MJ; Loeb LA; Swisher EM; Risques RA
    Proc Natl Acad Sci U S A; 2016 May; 113(21):6005-10. PubMed ID: 27152024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
    Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
    BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.